704 related articles for article (PubMed ID: 32918399)
1. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
2. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
[TBL] [Abstract][Full Text] [Related]
3. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
4. The importance of the interaction between hepatocyte and hepatic stellate cells in fibrogenesis induced by fatty accumulation.
Giraudi PJ; Becerra VJ; Marin V; Chavez-Tapia NC; Tiribelli C; Rosso N
Exp Mol Pathol; 2015 Feb; 98(1):85-92. PubMed ID: 25533546
[TBL] [Abstract][Full Text] [Related]
5. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
6. The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease.
Wilson RB; Chen YJ; Sutherland BG; Sawyez CG; Zhang R; Woolnough T; Hetherington AM; Peters KM; Patel K; Kennelly JP; Leonard KA; Schuurman M; Jacobs RL; Wang R; Borradaile NM
Pharmacol Res; 2020 Nov; 161():105208. PubMed ID: 32977024
[TBL] [Abstract][Full Text] [Related]
7. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
8. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis.
Sugino H; Kumagai N; Watanabe S; Toda K; Takeuchi O; Tsunematsu S; Morinaga S; Tsuchimoto K
J Gastroenterol Hepatol; 2008 Dec; 23(12):1909-16. PubMed ID: 18422963
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis.
Wang W; Zhao C; Zhou J; Zhen Z; Wang Y; Shen C
PLoS One; 2013; 8(10):e76538. PubMed ID: 24098525
[TBL] [Abstract][Full Text] [Related]
10. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
[TBL] [Abstract][Full Text] [Related]
11. Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis.
Bhattacharya D; Basta B; Mato JM; Craig A; Fernández-Ramos D; Lopitz-Otsoa F; Tsvirkun D; Hayardeny L; Chandar V; Schwartz RE; Villanueva A; Friedman SL
JHEP Rep; 2021 Jun; 3(3):100237. PubMed ID: 34151243
[TBL] [Abstract][Full Text] [Related]
12. Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis.
Pingitore P; Sasidharan K; Ekstrand M; Prill S; Lindén D; Romeo S
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30986904
[TBL] [Abstract][Full Text] [Related]
13. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
Deng YR; Ma HD; Tsuneyama K; Yang W; Wang YH; Lu FT; Liu CH; Liu P; He XS; Diehl AM; Gershwin ME; Lian ZX
J Autoimmun; 2013 Oct; 46():25-34. PubMed ID: 23948302
[TBL] [Abstract][Full Text] [Related]
14. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
Kimura T; Singh S; Tanaka N; Umemura T
Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
[TBL] [Abstract][Full Text] [Related]
15. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease.
Trasino SE; Tang XH; Jessurun J; Gudas LJ
J Mol Med (Berl); 2016 Oct; 94(10):1143-1151. PubMed ID: 27271256
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
17. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells.
Martí-Rodrigo A; Alegre F; Moragrega ÁB; García-García F; Martí-Rodrigo P; Fernández-Iglesias A; Gracia-Sancho J; Apostolova N; Esplugues JV; Blas-García A
Gut; 2020 May; 69(5):920-932. PubMed ID: 31530714
[TBL] [Abstract][Full Text] [Related]
18. The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis.
Wang Z; Li J; Xiao W; Long J; Zhang H
Lab Invest; 2018 Dec; 98(12):1600-1613. PubMed ID: 30206312
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease.
Liang D; Chen H; Zhao L; Zhang W; Hu J; Liu Z; Zhong P; Wang W; Wang J; Liang G
Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):133-142. PubMed ID: 29038049
[TBL] [Abstract][Full Text] [Related]
20. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease.
Lee J; Park JS; Roh YS
Arch Pharm Res; 2019 Nov; 42(11):935-946. PubMed ID: 31571145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
